ArticleStem cell research & therapy2025
Human umbilical cord-derived mesenchymal stromal cell exosomes ameliorate aging-associated skeletal muscle atrophy and dysfunction in SAMP10 mice.
Article in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Toward an Integrated Strategy for Volumetric Muscle Loss Regeneration.Journal of clinical medicine · 2026Review
- An injectable SFMA/HA-E hydrogel for sustained delivery of hucMSC-derived exosomes promotes myocardial repair after infarction.Stem cell research & therapy · 2026Article
- HECTD4 in human umbilical cord mesenchymal stem cells-derived exosomes alleviates osteoclast differentiation in osteoporosis progression by suppressing RANK m6A modification via promoting METTL3 ubiquitination.Journal of molecular histology · 2026Article
- Canine Adipose MSC-Derived Exosomes Ameliorate Skeletal Muscle Injury in Mice.Animals : an open access journal from MDPI · 2026Article
- Correction: Human umbilical cord-derived mesenchymal stromal cell exosomes ameliorate aging-associated skeletal muscle atrophy and dysfunction in SAMP10 mice.Stem cell research & therapy · 2025Article
- Umbilical cord mesenchymal stromal cells in sarcopenia: benefits and strategies for enhancing efficacy.Stem cell research & therapy · 2025Review
- Secretome from human placenta-derived mesenchymal stem cells repairs mechanically induced meniscus injury in mice by activating the proliferation and suppressing the apoptosis of endogenous meniscus progenitor cells.Stem cell research & therapy · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
8 authors.
Funding
Abstract
backgroundLoss of skeletal muscle mass and function in aging individuals is closely linked to physical deterioration and disability. Because exosomes of human umbilical cord-derived mesenchymal stem cells (hucMSC-Exos) have been widely used to treat various human diseases, we examined their effects on aging-associated muscle atrophy and dysfunction in senescence-accelerated mouse prone 10 (SAMP10) mice, an animal model of human Sarcopenia.
methodsTwenty-four-week-old male SAMP10 mice were randomly assigned to a non-treatment or hucMSC-Exos treatment group.
resultsTwelve weeks after intravenous injection of hucMSC-Exos, the treatment group mice showed improvements in skeletal muscle morphology and performance, and elevated levels of the proteins phospho-mammalian target of rapamycin (p-mTOR), myosin heavy chain (MHC), peroxisome proliferator-activated receptor-γ co-activator, and sirtuin1 (Sirt1) in gastrocnemius muscle tissues. HucMSC-Exos also improved muscle mitochondrial biogenesis and lipid drop accumulation in the gastrocnemius muscles. In in vitro experiments, hucMSC-Exos improved cell viability, senescence, apoptosis, and differentiation in association with induction of molecules related to anti-apoptosis (Bcl-2), differentiation (myogenin, MyoD1, myogenic factor-5, and myogenic factor-6), and protein anabolism (p-mTOR, MHC, Sirt1, phospho-AMP-activated protein kinase, phosphor-extracellular signal-regulated kinase1/2, and glycogen synthase kinase3alpha/beta) in C2C12 cells under our experimental conditions.
conclusionsOur findings indicate that hucMSC-Exos treatment ameliorated skeletal muscle atrophy and dysfunction via mitochondrial biogenesis, anti-apoptosis, and protein anabolism mechanisms that might be dependent on an mTOR and Sirt1/PGC1α signaling pathways, indicating that hucMSC-Exos may have promise as a treatment for the management of aging-related frailty and sarcopenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.